BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterinePress, Medical / Health ReportingBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerHealth TechnologyMedical Reporting
Updated on May 27, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Study Provides New Hope for Patients With Rare Cancers
A new study suggests that there's a way to predict which patients with rare cancers will benefit from a drug combination that boosts the immune system.
Many people with rare cancers lack good treatments, and drug companies don't develop any because of small potential sales, the Associated Press reported.
This U.S. National Cancer Institute-funded study pools these patients to give them strength in numbers and new options.
"For the patients that it works for, it's phenomenal, it's life-changing ... but it's not for everybody," said study co-leader, Dr. Sandip Patel of the University of California, San Diego's Moores Cancer Center, the AP reported.
Since it started in 2017, the study has enrolled more than 550 patients in the U.S. and Canada. Currently, it's testing a combo of two immunotherapy drugs, Opdivo and Yervoy in people grouped according to their tumor type.
The research was presented Sunday at an American Association for Cancer Research conference in Atlanta.
China to Regulate All Fentanyl-Related Drugs
All fentanyl-related drugs will be regulated as a class of controlled substances, China announced Monday.
The change has long been urged by U.S. officials as a way to slow the supply of deadly opioids from China, the Associated Press reported.
China's new regulations take effect May 1.
American officials have said that China is the main source of synthetic opioids that arrive in the United States directly by mail or via Mexico, but China denies that claim, the AP reported.
China already had controls on 25 variants of fentanyl, as well as two precursors used to make the drug. U.S. Drug Enforcement Administration data show that when China bans a variant of fentanyl, seizures of that analog in the United States decline.
"We firmly believe that listing the entire class of fentanyl substances will completely block the loopholes that enable law breakers to evade punishment by simply modifying one or several atoms, functional groups or other groups," Liu Yuejin, vice commissioner of China's National Narcotics Control Commission, told the AP.
"It will effectively prevent the massive abuse of fentanyl substances and illegal drug trafficking and smuggling activities, and contribute to global drug control...," Liu added.
Blood Cancers Treatment Shows Promise Against Solid Tumors
An immune system-boosting treatment used to fight blood cancers shows early promise in treating some solid tumors, researchers report.
In CAR-T therapy, some of a patient's own cells are genetically modified to to help them recognize and attack cancer. CAR-T was approved in 2017 for some leukemias and lymphomas, the Associated Press reported.
Now, the effectiveness of CAR-T in treating solid tumors was assessed in 19 patients with mesothelioma, an aggressive cancer of the lining of the lungs, and two patients with lung and breast cancer that had spread to the chest lining.
After CAR-T, one patient was able to have surgery and radiation, and is doing well 20 months later with no further treatment. Fifteen other patients were well enough to start taking a drug that uses a different approach to bolster the immune system, the AP reported.
Results were available for 11 of the 15 patients. Two had signs of cancer disappear for about a year, but one later relapsed. Tumors shrank in six patients, but cancer returned in three.
Details on the cases were presented Sunday at an American Association for Cancer Research conference in Atlanta.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Read this Next
Other Trending Articles